EMAIL THIS PAGE TO A FRIEND

Bioscience reports

Neuronal and astrocyte dysfunction diverges from embryonic fibroblasts in the Ndufs4fky/fky mouse.


PMID 25312000

Abstract

Mitochondrial dysfunction causes a range of early-onset neurological diseases and contributes to neurodegenerative conditions. The mechanisms of neurological damage however are poorly understood, as accessing relevant tissue from patients is difficult, and appropriate models are limited. Hence, we assessed mitochondrial function in neurologically relevant primary cell lines from a CI (complex I) deficient Ndufs4 KO (knockout) mouse (Ndufs4fky/fky) modelling aspects of the mitochondrial disease LS (Leigh syndrome), as well as MEFs (mouse embryonic fibroblasts). Although CI structure and function were compromised in all Ndufs4fky/fky cell types, the mitochondrial membrane potential was selectively impaired in the MEFs, correlating with decreased CI-dependent ATP synthesis. In addition, increased ROS (reactive oxygen species) generation and altered sensitivity to cell death were only observed in Ndufs4fky/fky primary MEFs. In contrast, Ndufs4fky/fky primary isocortical neurons and primary isocortical astrocytes displayed only impaired ATP generation without mitochondrial membrane potential changes. Therefore the neurological dysfunction in the Ndufs4fky/fky mouse may partly originate from a more severe ATP depletion in neurons and astrocytes, even at the expense of maintaining the mitochondrial membrane potential. This may provide protection from cell death, but would ultimately compromise cell functionality in neurons and astrocytes. Furthermore, RET (reverse electron transfer) from complex II to CI appears more prominent in neurons than MEFs or astrocytes, and is attenuated in Ndufs4fky/fky cells.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

11699695001 ATP Bioluminescence Assay Kit CLS II
G0750
D-(+)-Galactose, ≥99%
C6H12O6
G0625
D-(+)-Galactose, ≥98%
C6H12O6
G6404
D-(+)-Galactose, BioXtra, pH 5.0-7.0 (20 °C, 1 M in H2O), ≥99%
C6H12O6
G5388
D-(+)-Galactose, powder, anhydrous, BioReagent, suitable for cell culture, suitable for insect cell culture
C6H12O6
48260
D-(+)-Galactose, for microbiology, ≥99.0%
C6H12O6
15522
D-(+)-Galactose, meets analytical specification of Ph. Eur., BP
C6H12O6
D7008
Dihydroethidium, ≥95%
C21H21N3
37291
Dihydroethidium, BioReagent, suitable for fluorescence, ≥95% (HPCE)
C21H21N3
1287700 Galactose, United States Pharmacopeia (USP) Reference Standard
C6H12O6
PHR1206
Galactose, Pharmaceutical Secondary Standard; Certified Reference Material
C6H12O6
G0050000
Galactose, European Pharmacopoeia (EP) Reference Standard
C6H12O6
ARK2176
Galactose, plant-derived, PharmaGrade, USP/NF, Ph Eur, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production.
C6H12O6
L4632
Lithium dodecyl sulfate, ≥98.5% (GC)
C12H25LiO4S
L9781
Lithium dodecyl sulfate, BioReagent, for molecular biology, suitable for electrophoresis
C12H25LiO4S
L5901
Lithium dodecyl sulfate, BioXtra, ≥98.5% (GC)
C12H25LiO4S
R8875
Rotenone, ≥95%
C23H22O6
45656
Rotenone, PESTANAL®, analytical standard
C23H22O6